Science Immunology

Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. Characterization of RIG-I–deficient B16.OVA clones.
  • Fig. S2. Tumor cell–intrinsic RIG-I signaling promotes localized cross-presentation of tumor-associated antigen by CD103+ DCs in TdLNs.
  • Fig. S3. Tumor cell–intrinsic RIG-I deficiency is associated with reduced TIL frequencies and decreased expression of proteins involved in T cell lytic function.
  • Fig. S4. Anti–CTLA-4–mediated antitumor immunity does not rely on tumor cell–derived IFN-I.
  • Fig. S5. Melanoma cell–intrinsic STING signaling induces IFN-I production but not programmed cell death.
  • Fig. S6. Local RIG-I activation renders poorly immunogenic tumors susceptible to checkpoint inhibition.
  • Fig. S7. Antitumor synergy between CTLA-4 blockade and local RIG-I activation is not restricted to melanoma.
  • Fig. S8. Proposed model: Tumor-intrinsic RIG-I signaling promotes checkpoint inhibitor–mediated anticancer immunity.
  • Legend for table S1
  • Table S2. Low RIG-I–encoding DDX58 expression in melanoma biopsies is an independent risk factor for death.
  • References (5357)

Download PDF

Other Supplementary Material for this manuscript includes the following:

  • Table S1. Single-gene data murine tumor RNA-seq (Excel).
  • Table S3. Raw data file (Excel).

Files in this Data Supplement: